




www.prostaaid.org

“Issue #286” August 2023

August 16th Guest Speakers



Dr. Desmond Pink

Dr. Pink is the lead researcher in the development and validation of the Nanostics diagnostics platform and has considerable expertise in scientific team management, as well as biochemistry, protein synthesis and experimental therapeutics. Dr. Pink earned his Ph.D. in Nutrition and Metabolism at the University of Alberta in Edmonton, Alberta.

Prior to joining Nanostics, he was the Senior Research Scientist and Project Manager at Entos Pharmaceuticals and Project Manager with Innovascreen Inc. Dr. Pink also investigated the cell signaling machinery of intestinal cancer cells as a Postdoctoral Fellow at Dalhousie University.



Dr. Argo Basu

Dr. Basu is currently employed at Nanostics, where he serves as the Clinical Laboratory Manager and Senior Scientist. In these roles, he not only oversees the Clinical Laboratory operations but also actively contributes to the development of innovative cancer tests. Driven by his deep-rooted interest in cancer diagnostics, he brings with him a wealth of experience in the diagnostic industry.

[Presidents Message](#)

Hi everyone! Hope you are all enjoying a beautiful Summer and that you had a fun filled Calgary Stampede.

Can you believe summer vacation is half over? PROSTAIID Calgary has continued to deliver services throughout the summer. We had a wonderful time at our first Warriors & Wives Partner and Caregiver picnic held at CKE Community Centre July 19th. We enjoyed some delicious fried chicken, potato salad, coleslaw, macaroni salad, buns and cookies. We shared stories and had some good laughs. Thank you to all the Warriors and their wives who made the evening such a great success. I can't wait for next year!

The Board of Directors has continued to meet and work on delivering quality speakers and events. We are still looking for additional Board members so please think about how you can help.

Lastly, I want to remind you all that we are a volunteer support group. Let's remember, there could be someone out there that might be hearing the words "you have prostate cancer" for the first time and would benefit from you sharing your experience whether you are a patient or a partner or caregiver. How can you support others?


Brad Sterling
President
PROSTAIID Calgary

Upcoming Events

Warriors & Wives Partners and Caregivers

Please come and join us on Wednesday, August 16th. We are meeting at CKE starting at 6:00 pm with a social gathering in the lounge and separate meetings from 6:30 to 7:30 prior to the general meeting in the main hall.

We want to personally thank all of you who have volunteered for our Casino on October 2 and 3. Without your willingness to volunteer, we might not have made the necessary deadline so again a BIG thank you to all of you. There still might be a few more that need to be on standby just in case someone is unable to make their shift. Please contact Richard at program.director@prostaidd.org with the day and shift if you can help us.



Donate Today

PROSTAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

[Donate Today](#)

Connect With Us

Information
Phone 403 455 1916
info@prostaaid.org
Brad Sterling
President
president@prostaaid.org


[Connect With Us](#)

Support Groups

Frank Altin
Warriors
faltin@telusplanet.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaaid.org

[Meeting Info Here](#)

Articles Of Interest



Testing

This issue is devoted to advances in tests used to identify patients with prostate cancer and to better define possible treatment options. I have always envisioned this as equivalent to gathering military intelligence prior to the start of a war. The more you understand about your opponent, the better your strategy will be and the greater the odds you will defeat your enemy.

July 2022
Prostatepedia

[Testing](#)




Indigenous Men Less Likely to Receive PSA Testing

Indigenous men are less likely to receive prostate-specific antigen (PSA) testing and are more likely to be diagnosed with higher-risk prostate cancer.

July 2023
Renal&Urology News

[Indigenous PSA](#)



Oral chemotherapy shows initial promise in treatment-resistant prostate cancer

"The beauty is, now we can deliver a cisplatin-based chemotherapeutic orally, which is usually never done. And by targeting the prostate, we can reduce kidney and liver toxicity and the risk of peripheral neuropathy," says Shanta Dhar, PhD.

July 2023
Urology Times

Oral Chemotherapy




Insights on Perirectal Spacing in Prostate Cancer

Perirectal spacing increases the distance between the prostate, which is the target organ for radiation, and the rectum. By increasing that space, you reduce the dose of radiation to unintended structures, the rectum, which lowers the adverse effect profile. Increasing the distance between the target and the non-target organs is important with perirectal spacing.

July 2023
Urology Times

Perirectal Spacing




Prostate Cancer Diagnoses Less Likely in Obese Men

Men with obesity are less likely to be diagnosed with prostate cancer but more likely to die from it compared with men who have a normal body mass index (BMI),

July 2023
Renal&Urology News

Less Likely



Biomarker Guides Optimal Duration of Androgen Deprivation Therapy

Androgen deprivation therapy (ADT) has long been established as an effective treatment option for high-risk localized prostate cancer (PC) when combined with radiotherapy (RT). However, determining the optimal duration of ADT remains a challenge.

July 2023
Oncology Times

Androgen Deprivation Therapy



The complex bacterial colonization of penile implants

In the treatment of refractory erectile dysfunction, penile prostheses can be an effective surgical option. Implants have advanced considerably since first introduced in the 1950s, including developments in anti-infective irrigants and coatings to help prevent infection.

July 2023
Urology Times

Penile Implants

Thank you to our Sponsors and Community Partners




Read more articles below

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



For Caregivers & Families



Where are the Men in Cancer Support?

While finding cancer survivor stories about men isn't a difficult endeavor, women are not only more likely to tell their own story, but in many cases, men's stories are told by women. This is even before we take into account the act of caretaking, which is dominated, almost exclusively, by women.

June 2023
CCSN

[Cancer Support](#)



Specialized Training and Education of Care Providers in Prostate Cancer

Focused discussion on the quality of training and onboarding of physicians who manage advanced prostate cancer within a variety of institutions and settings.

July 2023
Urology Times

[Watch The Video](#)

Articles For Everyone



Managing Erectile Dysfunction

Some treatments for prostate cancer, such as prostatectomy and radiotherapy, can cause damage to the nerves and blood vessels needed for an erection. Other treatments, such as hormone therapy, reduce the amount of testosterone in the body, which can reduce your sex drive and also lead to problems getting and maintaining an erection.
Prostate Cancer Research

[Erectile Dysfunction](#)



Cardiorespiratory Fitness Tied to Reduced Cancer Incidence, Mortality in Men


Higher levels of cardiorespiratory fitness (CRF) are associated with a reduced risk for incidence and mortality from specific cancers among men, according to a study published online in JAMA Network Open.

July 2023

Renal&Urology News

Cardiorespiratory Fitness

New Videos



From the VISION Trial: Improved Patient Outcomes with Lutetium-PSMA-617 - Karim Fizazi

In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients.

June 2023

URO TODAY

PSMA-617



Remembering PROSTAID: 30 Years of Service

On the year of its 30th anniversary, two of PROSTAID's past-presidents and key figures, Ron Gorham and Bob Shiell, share their recollections of the organization, their journeys with prostate cancer and how far we've all come since 1993. Current president, Brad Sterling, also helps give us context with a little time warp as to how things were in the early days of the 1990s.

June 2023

Prostaids Calgary

Remembering 30 Years

[Unsubscribe](#)